SCI Abstract

search
+
Fewer breast cancers during post-treatment surveillance among patients initially staged using contrast-based imaging
Fewer breast cancers during post-treatment surveillance among patients initially staged using contrast-based imaging
The role of contrast-based imaging (CBI) at diagnosis in early breast cancer remains debated. More sensitive baseline stag...
History of the early development of aromatase inhibitors for treatment of breast cancer
History of the early development of aromatase inhibitors for treatment of breast cancer
To review the early history of the development of aromatase inhibitors for treatment of breast cancer by the Penn State He...
Low pectoralis major muscle mass predicts the risk of post-surgical bleeding after mastectomy in patients with breast cancer
Low pectoralis major muscle mass predicts the risk of post-surgical bleeding after mastectomy in patients with breast cancer
Post-surgical bleeding is a clinically relevant complication after mastectomy. Although high body mass index (BMI) is asso...
Body mass index-associated gut microbial taxa and functional pathways in women with benign and malignant breast disease
Body mass index-associated gut microbial taxa and functional pathways in women with benign and malignant breast disease
Obesity is an established risk factor for breast cancer and is associated with alterations in gut microbial composition. W...
Efficacy, safety, and biomarker analysis of neoadjuvant camrelizumab plus apatinib as a chemotherapy-free strategy for early-stage triple-negative breast cancer: a phase II study
Efficacy, safety, and biomarker analysis of neoadjuvant camrelizumab plus apatinib as a chemotherapy-free strategy for early-stage triple-negative breast cancer: a phase II study
Neoadjuvant chemotherapy, a cornerstone of early-stage triple-negative breast cancer (TNBC) treatment, has limited efficac...
Associations of neighborhood deprivation with breast cancer tumor genomics, targeted treatment use, and survival
Associations of neighborhood deprivation with breast cancer tumor genomics, targeted treatment use, and survival
Neighborhood environments appear to influence breast cancer biology and outcomes. This study evaluated somatic, treatment,...
Oestrogen receptor testing and initiation of adjuvant endocrine therapy in women with ductal carcinoma in situ: a population-based study
Oestrogen receptor testing and initiation of adjuvant endocrine therapy in women with ductal carcinoma in situ: a population-based study
Use of adjuvant endocrine therapy (ET) for ductal carcinoma in situ (DCIS) varies widely in clinical practice. We investig...
Anthracycline-containing versus anthracycline-free carboplatin-based regimens in early-stage triple-negative breast cancer: real-world outcomes
Anthracycline-containing versus anthracycline-free carboplatin-based regimens in early-stage triple-negative breast cancer: real-world outcomes
Triple‑negative breast cancer (TNBC) is an aggressive disease with poor survival outcomes. With the integration of i...
Exploring trop-2-directed ADCs monotherapy and combination therapy in pretreated mTNBC: a real-world study
Exploring trop-2-directed ADCs monotherapy and combination therapy in pretreated mTNBC: a real-world study
Although Trop-2 antibody-drug conjugates (ADCs) have improved outcomes in pretreated metastatic triple-negative breast can...
Real-world treatment patterns and clinical outcomes in patients with emerging estrogen receptor 1 (ESR1)-mutated ER+ metastatic breast cancer in the U.S., 2018-2024
Real-world treatment patterns and clinical outcomes in patients with emerging estrogen receptor 1 (ESR1)-mutated ER+ metastatic breast cancer in the U.S., 2018-2024
Clinical studies have highlighted the potential utility of monitoring for Estrogen receptor alpha 1 (ESR1) mutation (m) (E...
Real-world estrogen receptor alpha 1 () testing patterns and results for ER+/HER2- metastatic breast cancer in the United States, 2018–2024
Real-world estrogen receptor alpha 1 () testing patterns and results for ER+/HER2- metastatic breast cancer in the United States, 2018–2024
To understand historical and recent ESR1 testing rates, and when ESR1 mutations emerge during first-line (1 L) tr...
Trends in contralateral prophylactic mastectomy and genetic testing in the era of new society guidelines
Trends in contralateral prophylactic mastectomy and genetic testing in the era of new society guidelines
In 2016 and 2019 respectively, the American Society of Breast Surgeons published consensus statements discouraging contral...
Contemporary therapy for small node-negative triple-negative breast cancer: a retrospective cohort study
Contemporary therapy for small node-negative triple-negative breast cancer: a retrospective cohort study
Multi-agent neoadjuvant therapy (NAT) with immune checkpoint blockade is standard treatment for Stage II–III triple-...
Association between cumulative symptom burden and cognitive impairment among breast cancer survivors: a cross-sectional study
Association between cumulative symptom burden and cognitive impairment among breast cancer survivors: a cross-sectional study
Cancer-related cognitive impairment (CRCI) is a multifaceted symptom associated with various comorbid conditions, complica...
Efficacy, safety and circulating tumor cell dynamics in patients treated with Eribulin for HER2-negative advanced breast cancer – results from the phase II DETECT IVb trial
Efficacy, safety and circulating tumor cell dynamics in patients treated with Eribulin for HER2-negative advanced breast cancer – results from the phase II DETECT IVb trial
Eribulin is a non-taxane microtubule inhibitor that showed survival benefits for pretreated metastatic breast cancer (MBC)...
Integrin α2 (CD49b) blockade remodels the tumor immune microenvironment and enhances anti-PD-L1 therapy in 4T1 breast cancer model
Integrin α2 (CD49b) blockade remodels the tumor immune microenvironment and enhances anti-PD-L1 therapy in 4T1 breast cancer model
Collagen is a defining feature of breast tumors and is increasingly recognized as a regulator of tumor progression and imm...
Metastatic phenotype and post-metastatic survival across HER2-0, HER2-low, and HER2-positive breast cancer
Metastatic phenotype and post-metastatic survival across HER2-0, HER2-low, and HER2-positive breast cancer
HER2-low breast cancer is treatment-relevant, but whether it is clinically distinct from HER2-0 disease remains unclear. W...
Selected abstracts from the 7th Biannual International Invasive Lobular Carcinoma Symposium: Oral and Poster Presentations
Selected abstracts from the 7th Biannual International Invasive Lobular Carcinoma Symposium: Oral and Poster Presentations
Publication of this supplement was funded by the National Cancer Institute Grant R13CA317942. All content was reviewed and...
Metastatic breast cancer through the Oncotype DX Breast Recurrence Score®: insights from a small cohort study
Metastatic breast cancer through the Oncotype DX Breast Recurrence Score®: insights from a small cohort study
To evaluate the feasibility of obtaining a 21-gene Oncotype DX Breast Recurrence Score® (RS) result from metastatic b...
Genomic and proteomic profiling of mutant metastatic hormone receptor-positive breast cancer and impact on clinical outcomes
Genomic and proteomic profiling of mutant metastatic hormone receptor-positive breast cancer and impact on clinical outcomes
GATA3 mutations are among the most common alterations in hormone receptor-positive (HR+) breast cancer (BC), yet these hav...
Utility of plasma circulating DNA tumor fraction in bone-only metastatic breast cancer: a real-world outcomes study
Utility of plasma circulating DNA tumor fraction in bone-only metastatic breast cancer: a real-world outcomes study
Bone metastases develop in 50–70% of patients with metastatic breast cancer (MBC), with around one-third having bone...
Efficacy and safety of entinostat plus exemestane in hormone receptor-positive breast cancer: a systematic review meta-analysis of randomized controlled trials
Efficacy and safety of entinostat plus exemestane in hormone receptor-positive breast cancer: a systematic review meta-analysis of randomized controlled trials
Hormone receptor-positive (HR+) breast cancer continues to be a significant global challenge, as resistance to endocrine t...
Breast imaging recommendations for young females (age < 40 years) with ≥ 20% lifetime breast cancer risk: practice patterns at a specialized clinic
Breast imaging recommendations for young females (age < 40 years) with ≥ 20% lifetime breast cancer risk: practice patterns at a specialized clinic
The National Comprehensive Cancer Network (NCCN) and American Cancer Society (ACS) endorse differing guidelines for screen...
A mixed-methods study characterizing experiences of medical oncologists’ use of gonadotropin-releasing hormone agonists for treatment of breast cancer
A mixed-methods study characterizing experiences of medical oncologists’ use of gonadotropin-releasing hormone agonists for treatment of breast cancer
The use of ovarian function suppression (OFS) for the treatment of breast cancer in pre-menopausal women is low and little...
National trends in neoadjuvant systemic therapy utilization in patients with early-stage HER2-positive breast cancer from 2016–2021: The impact of the KATHERINE trial
National trends in neoadjuvant systemic therapy utilization in patients with early-stage HER2-positive breast cancer from 2016–2021: The impact of the KATHERINE trial
Neoadjuvant systemic therapy (NST) for HER2 + breast cancer (HER2 + BC) has historically been used...
Insurer and patient costs for repeat breast surgery after initial lumpectomy for breast cancer
Insurer and patient costs for repeat breast surgery after initial lumpectomy for breast cancer
 ~ 14–25% of patients who undergo a primary lumpectomy for the treatment of breast cancer require a reop...
Continuous glucose monitoring to characterize hyperglycemia during chemotherapy for early stage breast cancer
Continuous glucose monitoring to characterize hyperglycemia during chemotherapy for early stage breast cancer
Diabetes (DM) and hyperglycemia during chemotherapy increase the risk of toxicity, yet the prevalence and patterns of hype...
Phase I/II trial investigating gedatolisib plus talazoparib in advanced triple negative or BRCA1/2 positive, HER2 negative breast cancers
Phase I/II trial investigating gedatolisib plus talazoparib in advanced triple negative or BRCA1/2 positive, HER2 negative breast cancers
Metastatic triple negative breast cancer has a poor prognosis with limited targeted treatment options. In preclinical stud...
Tumoral pSMAD2 as a prognostic biomarker in early-stage breast cancer: insights from the randomized SweBCG91RT trial
Tumoral pSMAD2 as a prognostic biomarker in early-stage breast cancer: insights from the randomized SweBCG91RT trial
The TGF-β pathway can influence breast cancer progression and therapy efficacy, exhibiting both pro- and anti-tumoral...
PD-L1 22C3 CPS in paired primary breast cancer and lung metastasis
PD-L1 22C3 CPS in paired primary breast cancer and lung metastasis
This study aimed to evaluate the expression of PD-L1 22C3 in primary breast cancer and lung metastasis tissues using the C...
Load More
format_indent_increase